Most Read Articles
Pearl Toh, Yesterday
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
4 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Ruxolitinib effective, safe for atopic dermatitis

18 Feb 2020

Treatment with the selective inhibitor of Janus kinase 1 and 2 ruxolitinib leads to quick and stable improvements in atopic dermatitis (AD) symptoms, reports a recent phase II study.

Researchers enrolled 307 adult AD patients with mild or moderate disease, affecting 3–20 percent of the body surface area. Participants were randomly assigned to ruxolitinib (1.5% twice-daily, 1.5% once-daily, 0.5% once-daily and 0.15% once-daily), triamcinolone cream (0.1% twice-daily for 4 weeks, then vehicle for the next 4 weeks) or vehicle. Mean change in the Eczema Area and Severity Index (EASI) was the primary outcome.

All concentrations of the ruxolitinib cream resulted in significant EASI improvements at weeks 2, 4 and 8, with efficacy increasing over time and with higher concentrations.

In particular, the 1.5% ruxolitinib cream delivered twice-daily provided significantly better symptom relief at week 4 as compared with the vehicle treatment (71.6 percent vs 15.5 percent; p<0.0001). Both once- and twice-daily applications of 1.5% ruxolitinib also demonstrated numerical advantage over triamcinolone at week 4, though statistical significance was not achieved.

Moreover, 1.5% ruxolitinib twice-daily led to a greater reduction in itch numerical rating scale scores relative to the vehicle. This effect achieved significance as early as within 36 hours of treatment initiation (change, –1.8 vs –0.2 points; p<0.0001) and persisted over the remaining 12 weeks of treatment.

Ruxolitinib also proved to be safe, triggering no clinically significant application-site reactions. Three patients discontinued the trial due to treatment-emergent adverse events that were ultimately deemed unrelated to the event. One had been given 0.15% ruxolitinib, one vehicle and the final triamcinolone. All treatment-related adverse events were mild or moderate in severity.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
4 days ago
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.